Myfenax (Mycophenolate Mofetil)

Mycophenolate mofetil is converted in the body to mycophenolic acid, which blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This enzyme is essential for the de novo synthesis of guanosine nucleotides, a pathway that activated T‑ and B‑lymphocytes rely on. Inhibition reduces nucleotide availability, suppressing lymphocyte proliferation and dampening the immune response.

The appropriate dose of Myfenax is determined by the prescribing clinician based on the specific indication, the patient’s renal and hepatic function, and other individual factors. Healthcare providers set the regimen according to current clinical guidelines and patient needs.

Safety of Myfenax during pregnancy and lactation has not been established, and the pregnancy category is listed as unknown. Because mycophenolate mofetil may cause fetal toxicity, it is generally avoided in pregnant women and not recommended for breastfeeding mothers.

To request Myfenax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and import documentation.

The primary alternative to mycophenolate mofetil is azathioprine, another antimetabolite. Mycophenolate offers more selective inhibition of lymphocyte proliferation with a lower incidence of certain toxicities such as hepatotoxicity, but both agents require monitoring for bone‑marrow suppression and infection risk. Choice depends on patient tolerance, organ function and transplant protocol.

Myfenax tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in areas with high humidity or extreme heat, and keep out of reach of children.

Myfenax is supplied as an oral tablet taken by mouth. It may be taken with or without food, according to the prescribing clinician’s instructions. Patients should swallow the tablet whole and follow the dosing schedule provided by their healthcare professional.

Serious risks include severe infections (including opportunistic pathogens), bone‑marrow suppression leading to low blood counts, hepatic toxicity, increased risk of certain malignancies with long‑term use, and potential teratogenic effects. Patients should report fever, unusual bruising, jaundice or any signs of infection promptly.

Myfenax should be avoided in individuals with known hypersensitivity to mycophenolate mofetil, severe renal impairment, uncontrolled active infections, and in pregnant women. Caution is also advised for patients with significant hepatic disease or those receiving other myelosuppressive agents.